Prevention and Treatment of Trichomoniasis

1. Treatment of Trichomoniasis

1.1. Main Treatment Medications and Mechanism of Action

Trichomoniasis is a disease that can be effectively treated and cured with medication. The main class of antibiotics known to be effective against T. vaginalis is nitroimidazole. The most common drugs in this group are metronidazole and tinidazole. Secnidazole is also another treatment option. These drugs work by interfering with the parasite’s DNA synthesis process, leading to their destruction.

1.2. Recommended Treatment Regimens according to CDC and WHO Guidelines

Treatment guidelines from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend specific regimens for men and women:

• For Women: The recommended regimen is Metronidazole 500 mg orally twice daily for 7 days.

• For Men: The recommended regimen is Metronidazole 2 g orally as a single dose.

• Alternative Regimen (for both men and women): Tinidazole 2 g orally as a single dose. Tinidazole is often more expensive but can achieve higher concentrations in the serum and urogenital tract, has a longer half-life than metronidazole, and fewer gastrointestinal side effects.

A critical note is the avoidance of alcohol during treatment with nitroimidazoles. Traditionally, alcohol abstinence has been recommended for 24 hours after metronidazole and 72 hours after tinidazole to avoid a disulfiram-like reaction. However, recent CDC guidelines suggest that limited alcohol consumption (no more than one drink per day) may be acceptable when taking metronidazole, as direct inhibition of acetaldehyde dehydrogenase is not observed.

1.3. Treatment for Pregnant and Breastfeeding Women

Treatment of Trichomoniasis during pregnancy is very important due to potential risks to the fetus. Metronidazole is considered safe for pregnant women. Pregnant patients can receive a metronidazole regimen similar to non-pregnant patients (Metronidazole 500 mg twice daily for 7 days). Although some clinicians may prefer to delay treatment until the second trimester, timely treatment is necessary once the diagnosis is confirmed. For breastfeeding women, metronidazole passes into breast milk and may affect the taste. Manufacturers recommend avoiding high doses or interrupting breastfeeding for 12-24 hours after a single dose to reduce infant exposure. Tinidazole and Secnidazole are generally not recommended for pregnant women due to a lack of adequate safety studies. Tinidazole is classified as a Category C drug in pregnancy, and the manufacturer contraindicates its use in the first trimester.

1.4. Partner Management to Prevent Reinfection with Trichomoniasis

To achieve long-term treatment effectiveness and prevent reinfection, partner management is an extremely critical factor. About 1 in 5 people become reinfected within 3 months after treatment. This usually happens if sexual intercourse occurs without a condom with an untreated partner. Therefore, to avoid reinfection, all sexual partners must be treated at the same time as the patient. Patients should abstain from sexual activity until both the patient and all partners have completed treatment and all symptoms have disappeared, usually about 7-10 days after finishing the medication course. The high rate of reinfection despite the possibility of a cure highlights the challenges in partner notification and adherence to treatment and abstinence guidelines. This emphasizes that public health efforts need to improve strategies for partner services (notification, testing, treatment), and patient counseling must strongly emphasize the importance of partner treatment and temporary abstinence to achieve a lasting cure and prevent community spread.

1.5. Managing Cases of Reinfection or Drug Resistance

In some cases, Trichomoniasis can recur or become drug-resistant, making treatment difficult. Recurrent cases may be due to non-adherence to treatment (not taking the full dose or for the full duration), reinfection from an untreated partner, or the parasite having developed resistance to metronidazole. Metronidazole resistance occurs in 4-10% of vaginal Trichomoniasis cases. If symptoms persist after the initial therapy, these possibilities should be considered. For the first treatment failure, retreatment with metronidazole 500mg orally twice daily for 7 days is recommended. If this second treatment fails, metronidazole 2g orally once daily for 3-5 days may be used. For persistent treatment failure, expert consultation and consideration of T. vaginalis metronidazole susceptibility testing are required. The CDC provides recommendations for managing recurrent/persistent Trichomoniasis and performing susceptibility testing for refractory cases. Tinidazole can be effective against some metronidazole-resistant strains. Other alternative regimens tested for resistant cases include high-dose metronidazole (2g daily for 7 days) or tinidazole (2g daily for 14 days along with 500mg vaginal tinidazole twice daily).

2. Prevention of Trichomonas Infection

2.1. Effective Prevention Measures for Both Men and Women

The only way to completely avoid all STIs, including Trichomoniasis, is to abstain from vaginal, anal, or oral sex. However, if sexually active, the risk of infection can be significantly reduced by adopting the following measures:

• Monogamy: Maintain a long-term, mutually monogamous relationship with a partner who has been tested and is negative for STIs, and only have sexual intercourse with that one partner.
• Correct Condom Use: Use a latex condom correctly every time you have sexual intercourse. It is crucial to put the condom on before the penis touches the vagina, mouth, or anus. However, it should be noted that the parasite T. vaginalis can infect skin areas not covered by the condom, so condoms may not provide complete protection in all cases. Acknowledging the incomplete protection of condoms against Trichomoniasis due to skin-to-skin contact outside the covered areas is an important nuance for informed prevention. This suggests that Trichomoniasis prevention strategies should emphasize a multifaceted approach, including monogamy, partner testing, and open communication, in addition to condom use.
• Open Communication: Discuss potential STI risks with new partners before sexual intercourse.
• Limit the Number of Partners: Reducing the number of sexual partners also helps reduce the risk of exposure.
• Avoid Vaginal Douching: Do not douche the vagina, as this can eliminate the natural beneficial bacteria in the vagina, increasing the risk of infection.
• Avoid Substance Abuse: Avoid abusing alcohol or illegal drugs, as they can impair judgment and lead to risky sexual behavior.
• Understand Ineffective Measures: Washing genitals, urinating, or douching after sexual intercourse will not prevent any STI.

2.2. Regular Screening and Sexual Health Counseling for High-Risk Groups

Regular screening and sexual health counseling play a vital role in preventing and controlling Trichomoniasis, especially for high-risk groups. Routine testing for Trichomoniasis and other STIs is recommended. Open and honest communication with partners about sexual history and potential risks is an essential part of effective prevention. Prevention counseling should be offered to all sexually active adolescents and high-risk adults. While screening is not generally recommended for asymptomatic women, it can be considered in areas with high prevalence or for women at high risk, such as those with multiple partners, sex in exchange for money, use of illegal drugs, or a history of STIs. The CDC specifically recommends routine screening for T. vaginalis for asymptomatic people with HIV infection. Refer to tests for gynecological conditions at:

• The Importance of Accurate Testing and Treatment in Gynecological Issues

3. Post-Treatment Follow-up and Risk of Reinfection

3.1. Follow-up Schedule and Retesting

After completing treatment for Trichomoniasis, follow-up is necessary to ensure the infection has been completely eliminated and to prevent reinfection. For women with a positive test result for Trichomoniasis, retesting is recommended 3 months after treatment. The primary purpose of this retesting is to detect any cases of reinfection. For men, retesting is generally not necessary unless symptoms return. If any symptoms of Trichomoniasis reappear after treatment, both men and women should seek medical care again immediately for evaluation and timely treatment.

3.2. Factors that Increase the Risk of Reinfection

Reinfection with Trichomoniasis is a common problem, with about 1 in 5 people becoming reinfected within 3 months after the initial treatment. This can happen if sexual intercourse occurs without a condom with a partner who is still infected with Trichomoniasis. Reinfection is particularly common in sexually active people. Key factors that increase the risk of reinfection include: inadequate treatment (not completing the full course or not taking the correct dose), reinfection from an untreated partner, or in rare cases, the parasite having developed resistance to metronidazole. The high rate of reinfection despite the possibility of a cure indicates challenges in partner notification and adherence to treatment and abstinence guidelines. Simultaneous partner management and abstinence from sexual intercourse until both parties have completed treatment and are symptom-free is crucial to break the chain of transmission and achieve long-term treatment effectiveness.

4. Conclusion

Trichomoniasis, caused by the parasite Trichomonas vaginalis, is the most common non-viral sexually transmitted infection globally. Although curable, the high prevalence and large number of asymptomatic cases have created significant challenges in controlling the disease. The high asymptomatic rate (about 70%) means many people are unaware they are infected and unintentionally transmit the disease, making symptom-based diagnosis unreliable and hindering prevention efforts. For prevention, safe sexual practices such as maintaining monogamy, correct condom use, and limiting the number of partners are crucial. However, it should be noted that condoms may not provide complete protection due to the potential for transmission through skin-to-skin contact in uncovered areas. Regular screening, especially in high-risk groups such as women with HIV or those with multiple partners, along with open sexual health counseling, are essential strategies for controlling the spread of the disease. The high rate of co-infection with other STIs also emphasizes the need for comprehensive screening when Trichomoniasis is diagnosed.

This article is written by Dr Đỗ Hữu Đạt. The doctor has many years of in-depth experience in reproductive and sexual health care.